845616-81-1

Basic information

• Product Name: 1-(3-Fluoro-5-trifluoroMethylpyridin-2-yl)piperazine
• Synonyms: 1-(3-Fluoro-5-trifluoroMethylpyridin-2-yl)piperazine;1-(3-Fluoro-5-trifluoroMethylpyridin-2-yl)
• CAS NO: 845616-81-1
• Molecular Formula: C₁₀H₁₁F₄N₃
• Molecular Weight: 249.2080528
• Mol File: 845616-81-1.mol

Chemical Properties

• Boiling Point: 308.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.320±0.06 g/cm3(Predicted)
• PKA: 8.24±0.10(Predicted)
• CAS DataBase Reference: 1-(3-Fluoro-5-trifluoroMethylpyridin-2-yl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-Fluoro-5-trifluoroMethylpyridin-2-yl)piperazine(845616-81-1)
• EPA Substance Registry System: 1-(3-Fluoro-5-trifluoroMethylpyridin-2-yl)piperazine(845616-81-1)

Safety Data

• Hazardous Substances Data: 845616-81-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(3-Fluoro-5-trifluoroMethylpyridin-2-yl)piperazine is used as a building block for the synthesis of various pharmaceuticals for its potential therapeutic applications in treating a range of diseases and disorders.
Used in Drug Discovery and Development:
1-(3-Fluoro-5-trifluoroMethylpyridin-2-yl)piperazine is used as a valuable tool in drug discovery and development due to its unique structural features and potential applications in neuroscience, oncology, and infectious diseases.
Used in Research Settings:
1-(3-Fluoro-5-trifluoroMethylpyridin-2-yl)piperazine is used in research settings for its diverse pharmacological properties and structural versatility, which may contribute to the development of new therapeutic agents and understanding of various biological processes.

Upstream product

• 110-85-0 piperazine 
• 89402-42-6 2,3-difluoro-5-(trifluoromethyl)pyridine 
• 72600-67-0 2-chloro-3-fluoro-5-(trifluoromethyl)pyridine 
• 72587-15-6 2-chloro-3-nitro-5-(trifluoromethyl)pyridine 
• 897376-76-0 4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1055353-53-1 C₂₀H₂₁F₄N₃O₄S 
• 845614-11-1 Bitopertin 

Relevant articles and documents

MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2

The present application provides a compound of Formula: or a pharmaceutically acceptable salt thereof, wherein ring B, L1, ring A, L2, n, R1, R2, R3, R4, and X1 are as described herein. Pharmaceutical compositions comprising the compound, as well as the methods of making and using the compound, are also provided.

2-Substituted-oxy-5-methylsulfonyl pyridine piperazine acidamide analogue and preparation method and application thereof

The invention discloses 2-substituted-oxy-5-methylsulfonyl pyridine piperazine acidamide analogue and a preparation method and application thereof, and particularly, relates to 2-substituted-oxy-5-methylsulfonyl pyridine piperazine acidamide analogue with

Selective GlyT1 inhibitors: Discovery of [4-(3-fluoro-5- trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2, 2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia

The GlyT1 transporter has emerged as a key novel target for the treatment of schizophrenia. Herein, we report on the optimization of the 2-alkoxy-5-methylsulfonebenzoylpiperazine class of GlyT1 inhibitors to improve hERG channel selectivity and brain penetration. This effort culminated in the discovery of compound 10a (RG1678), the first potent and selective GlyT1 inhibitor to have a beneficial effect in schizophrenic patients in a phase II clinical trial.

SYNTHESIS OF GLYT-1 INHIBITORS

The present invention relates to a process for preparation of a compound of formula I wherein Het, R1, R2, R3, and n are as defined herein and pharmaceutically acceptable acid addition salts thereof, which comprises reacting a compound of formula 21 with a compound of formula 8 to obtain a compound of formula 11 and coupling the compound of formula 11 in the presence of a coupling reagent or the corresponding acid halogenide with a compound of formula 15 to obtain a compound of formula I.

CAMPHOR-DERIVED CXCR3 ANTAGONISTS

The instant invention related to camphor derivatives of which are useful in treating diseases wherein inhibition of the exzyme CXCR3 results in beneficial therapy in a mammal.

Sulfanyl substituted phenyl methanones

The present invention relates to compounds of formula I wherein R1, R2, R3, X, X1, and n are as defined in the specification and pharmaceutically acceptable acid addition salts thereof. These compounds are good inhibitors of the glycine transporter 1 (GlyT-1) for the treatment CNS disorders, such as schizophrenia, cognitive impairment, and Alzheimer's disease.